1 min read

Cleerly's AI scans comparable to gold-standard angiography

Only a few months after it emerged from stealth and burst onto the medtech scene, Cleerly is already living up to its name.

By Andrea Park

The newly published results of a study show that the New York City-based startup’s artificial intelligence-powered software does, indeed, allow healthcare providers to (ahem) clearly spot signs of heart disease without requiring the invasive evaluations that make up the current gold standard for coronary artery disease diagnosis.

In the latter method, the coronary angiogram, a catheter is threaded through the arm or leg to reach the heart, where it injects dye into its arteries so X-ray images can capture how blood flows through the vessels. Though serious complications from the procedure are rare, they potentially include injury to the catheterized artery, an allergic reaction or kidney damage from the dye, as well as heart attack, stroke and more. Read the full article HERE.

AI Leading the Way to More Precise Diagnostics and Disease Risk Prediction

AI Leading the Way to More Precise Diagnostics and Disease Risk Prediction

Inside Precision Medicine features our Chief Scientific Officer, Dr. Udo Hoffmann, on how AI has changed CT imaging and the TRANSFORM trial that may...

Read More
Digital Health 50: The Most Promising Digital Health Companies of 2023

Digital Health 50: The Most Promising Digital Health Companies of 2023

Selected from more than 10,000 private healthcare companies, Cleerly is named one of CB Insight’s Digital Health 50 based on R&D, Mosaic scores,...

Read More
In Pursuit Of: Brilliant Minds in Healthcare

In Pursuit Of: Brilliant Minds in Healthcare

Nasdaq interviews CEO Dr. James K. Min, one of their 18 “Brilliant Minds in Healthcare,” about Cleerly’s founding, his vision for the company, and...

Read More